GALAPAGOS
GALAPAGOS NV, commonly referred to as Galapagos, is a pioneering biotechnology company headquartered in the United States, with significant operations in Europe. Founded in 1999, Galapagos has established itself in the pharmaceutical industry, focusing on the discovery and development of innovative medicines for various diseases, including inflammatory and fibrotic conditions. The company is renowned for its unique drug discovery platform, which leverages advanced technologies to identify and develop novel therapeutic candidates. Notable achievements include the successful development of several clinical-stage programmes, positioning Galapagos as a leader in the biopharmaceutical sector. With a commitment to scientific excellence and a robust pipeline, Galapagos continues to make significant strides in transforming patient care through groundbreaking therapies.
DitchCarbon Score
How does GALAPAGOS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GALAPAGOS's score of 44 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GALAPAGOS's reported carbon emissions
In 2023, GALAPAGOS reported total carbon emissions of approximately 40,000,000 kg CO2e. This figure includes 2,922,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 1,132,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The majority of their emissions, about 36,537,000 kg CO2e, fall under Scope 3, which encompasses all other indirect emissions in the value chain. Notably, the largest contributors to Scope 3 emissions include purchased goods and services (28,257,000 kg CO2e) and capital goods (4,534,000 kg CO2e). Comparatively, in 2022, GALAPAGOS's total emissions were approximately 54,609,000 kg CO2e, with Scope 1 emissions at 3,180,000 kg CO2e and Scope 2 emissions at 849,000 kg CO2e. The Scope 3 emissions for that year were significantly higher at about 54,609,000 kg CO2e, indicating a substantial reduction in total emissions from 2022 to 2023. Despite these figures, GALAPAGOS has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi) for emissions reduction. Their climate commitments remain vague, with no documented reduction targets or climate pledges available.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 3,180,000 | 0,000,000 |
| Scope 2 | 217,000 | 000,000 |
| Scope 3 | 54,609,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GALAPAGOS is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
